China Pharma Holdings
CPHIChina Pharma Holdings, Inc. (NASDAQ: CPHI) is a specialty pharmaceutical company based in the People’s Republic of China. The company’s primary business is the development, manufacturing, and marketing of both generic and branded pharmaceutical products. Its product portfolio is comprised primarily of finished dosage forms, which include powders, tablets, capsules, and ointments. The company operates through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., which manages its manufacturing and distribution activities. The company’s products are designed for the treatment of a range of conditions. Key therapeutic areas addressed by its portfolio include the central nervous system, cardiovascular system, digestive tract, and anti-infective applications. This positions the company within several major segments of the generic pharmaceutical market in China. Its operations encompass the entire pharmaceutical value chain from active pharmaceutical ingredient (API) processing to final product packaging. As a publicly traded entity, China Pharma Holdings is subject to the reporting requirements of the U.S. Securities and Exchange Commission. The company’s strategic focus remains on the manufacturing and distribution of pharmaceutical products within the Chinese healthcare market. Its business model is centered on the production of standardized dosage forms for widespread therapeutic use.
CPHI · Stock Price
Historical price data
About
China Pharma Holdings, Inc. (NASDAQ: CPHI) is a specialty pharmaceutical company based in the People’s Republic of China. The company’s primary business is the development, manufacturing, and marketing of both generic and branded pharmaceutical products. Its product portfolio is comprised primarily of finished dosage forms, which include powders, tablets, capsules, and ointments. The company operates through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., which manages its manufacturing and distribution activities. The company’s products are designed for the treatment of a range of conditions. Key therapeutic areas addressed by its portfolio include the central nervous system, cardiovascular system, digestive tract, and anti-infective applications. This positions the company within several major segments of the generic pharmaceutical market in China. Its operations encompass the entire pharmaceutical value chain from active pharmaceutical ingredient (API) processing to final product packaging. As a publicly traded entity, China Pharma Holdings is subject to the reporting requirements of the U.S. Securities and Exchange Commission. The company’s strategic focus remains on the manufacturing and distribution of pharmaceutical products within the Chinese healthcare market. Its business model is centered on the production of standardized dosage forms for widespread therapeutic use.